Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is an underdiagnosed, progressive, and fatal multisystemic disease with a heterogenous clinical phenotype that is caused by TTR gene mutations that destabilize the TTR protein, resulting in its misfolding, aggregation, and deposition in tissues throughout the body.Areas covered: Inotersen, an antisense oligonucleotide inhibitor, was recently approved in the United States and Europe for the treatment of the polyneuropathy of ATTRv based on the positive results obtained in the pivotal phase 3 trial, NEURO-TTR. This review will discuss the mechanism of action of inotersen and its pharmacology, clinical efficacy, and safety and tolerability. A PubMed search using the terms ‘inotersen,’ ‘AG10,’ ‘antisense oligonucleotide,’ ‘hereditary transthyretin amyloidosis,’ ‘familial amyloid polyneuropathy,’ and ‘familial amyloid cardiomyopathy’ was performed, and the results were screened for the most relevant English language publications. The bibliographies of all retrieved articles were manually searched to identify additional studies of relevance.Expert opinion: Inotersen targets the disease-forming protein, TTR, and has been shown to improve quality of life and neuropathy progression in patients with stage 1 or 2 ATTRv with polyneuropathy. Inotersen is well tolerated, with a manageable safety profile through regular monitoring for the development of glomerulonephritis or thrombocytopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
From CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis (2021) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Self-citationInotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationTafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Self-citationGuideline of transthyretin-related hereditary amyloidosis for clinicians
Ando, Y., Coelho, T., Berk, J. L., Cruz, M. W., Ericzon, B.-G., Ikeda, S.-I., Lewis, W. D., Obici, L., Planté-Bordeneuve, V., Rapezzi, C., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-31 · Cited by 719
Self-citationRepurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial
Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., et al. (2013) · JAMA · doi:10.1001/jama.2013.283815 · Cited by 708
Self-citationHolmgren, G., Steen, L., Suhr, O., Ericzon, B.-G., Groth, C.-G., Andersen, O., Wallin, B. G., Seymour, A., Richardson, S., Hawkins, P. N., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)93127-m · Cited by 579
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component
Richards, D. B., Cookson, L. M., Berges, A. C., Barton, S. V., Lane, T., Ritter, J. M., Fontana, M., Moon, J. C., Pinzani, M., Gillmore, J. D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504942 · Cited by 378
Coelho, T., Maurer, M. S., & Suhr, O. B. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.754348 · Cited by 339
Ericzon, B.-G., Wilczek, H. E., Larsson, M., Wijayatunga, P., Stangou, A., Pena, J. R., Furtado, E., Barroso, E., Daniel, J., Samuel, D., et al. (2015) · Transplantation · doi:10.1097/tp.0000000000000574 · Cited by 314
Self-citation
Research works printed but not linked: 6
- 2. Coelho T, Ericzon BG, Falk R, et al. A guide to transthyretin amyloidosis. Clarkston, MI: Amyloidosis Foundation; 2016 cited 2019 Mar 27. http://www.amyloidosis.org/wp-content/uploads/2017/05/ 2017-ATTR-guide.pdf
- 5. Gertz MA. Hereditary attr amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107 -s112. - Review describing the multisystemic clinical presentation of ATTRv, the diagnosis and monitoring of ATTRv, and available treatment options.
- 25. Vyndaqel [summary of product characteristics]. Bruxelles, Belgium: Pfizer Europe MA EEIG; 2018.
- 32. Vyndaqel [prescribing information]. New York, NY: Pfizer Labs; 2019 May.
- 47. Tegsedi [prescribing information]. Boston, MA: Akcea Therapeutics; October2018 - The US prescribing information for inotersen
- 51. Tegsedi [summary of product characteristics]. London, UK: Akcea Therapeutics UK Ltd.; 2018.
Cited by
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Zhang, H., Vandesompele, J., Braeckmans, K., Smedt, S. C. D., & Remaut, K. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00194f · Cited by 158
Migliorati, J. M., Liu, S., Liu, A., Gogate, A., Nair, S., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000417 · Cited by 123
Antisense drug discovery and development technology considered in a pharmacological context
Crooke, S. T., Liang, X., Crooke, R. M., Baker, B. F., & Geary, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114196 · Cited by 115
From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
Landmesser, U., Poller, W., Tsimikas, S., Most, P., Paneni, F., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa229 · Cited by 99
Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy
Sosnowska, B., Surma, S., & Banach, M. (2022) · Pharmaceuticals · doi:10.3390/ph15121573 · Cited by 71
Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
Sang, A., Zhuo, S., Bochanis, A., Manautou, J. E., Bahal, R., Zhong, X., & Rasmussen, T. P. (2024) · BioDrugs · doi:10.1007/s40259-024-00665-2 · Cited by 69
Clinical Pharmacokinetics of Approved RNA Therapeutics
Jo, S. J., Chae, S. U., Lee, C. B., & Bae, S. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010746 · Cited by 47
Gertz, M. A. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.02.005 · Cited by 34
Self-citationRNA-based therapy in the management of lipid disorders: a review
Blom, D. J., Marais, A. D., Moodley, R., van der Merwe, N., van Tonder, A., & Raal, F. J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01649-3 · Cited by 32
Long non-coding RNAs in immune regulation and their potential as therapeutic targets
Kumar, D. B. U., & Williams, A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106279 · Cited by 32
Sharma, A., Sharma, L. K., Nandy, S. K., Payal, N., Yadav, S., Vargas-De-La-Cruz, C. B., Anwer, M. K., Khan, H. Z., Behl, T., & BUNGAU, S. G. (2023) · Molecules · doi:10.3390/molecules28020750 · Cited by 31
Development and Clinical Applications of Antisense Oligonucleotide Gapmers
Chan, L., & Yokota, T. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0771-8_2 · Cited by 25
Synthetic Elaboration of Native DNA by RASS (SENDR)
Flood, D. T., Knouse, K. W., Vantourout, J. C., Kitamura, S., Sanchez, B. B., Sturgell, E., Chen, J. S., Wolan, D. W., Baran, P. S., & Dawson, P. E. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00680 · Cited by 25
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Poller, W. C., Sahoo, S., Hajjar, R. J., Landmesser, U., & Krichevsky, A. M. (2023) · Cells · doi:10.3390/cells12222660 · Cited by 22
Emerging Therapies for Transthyretin Amyloidosis
Tsoi, M. R., Lin, J., & Patel, A. R. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01397-2 · Cited by 12
Peterlin, B., Gualandi, F., Maver, A., Servidei, S., van der Maarel, S. M., Lamy, F., Méjat, A., Evangelista, T., & Ferlini, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239329 · Cited by 11
Michieli, L. D., Lupi, A., Sinigiani, G., Tietto, A., Salvalaggio, A., Branca, A., Pozzo, S. D., Rizzo, S., Cecchin, D., Marra, M. P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103481 · Cited by 10
Disease-modifying therapy for proteinopathies: Can the exception become the rule?
Bitan, G. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.010 · Cited by 10
Inotersen to Treat Polyneuropathy Associated with Hereditary Transthyretin (hATTR) Amyloidosis
Robinson, C., Pham, C. T., Zamarripa, A. M., Dugay, C., Lee, C. A., Berger, A. A., Landman, A., Cornett, E. M., Kassem, H., Kaye, A. D., et al. (2023) · Health Psychology Research · doi:10.52965/001c.67910 · Cited by 9
Innate Immunity in Cardiovascular Diseases—Identification of Novel Molecular Players and Targets
Poller, W. C., Heidecker, B., Ammirati, E., Kuss, A. W., Tzvetkova, A., Poller, W. C., Skurk, C., & Haghikia, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010335 · Cited by 8
Klaassen, S. H. C., van Veldhuisen, D. J., Nienhuis, H. L. A., van den Berg, M. P., Hazenberg, B. P. C., & van der Meer, P. (2020) · Cardiac failure review · doi:10.15420/cfr.2019.16 · Cited by 8
Olatunji, G. D., Kokori, E., Abraham, I. C., Omoworare, O. T., Olatunji, D., Ezeano, C., Babawale, E. A., Stanley, A. C., Oluwatobiloba, A. M., Oluwademilade, O. B., et al. (2024) · Medicine · doi:10.1097/md.0000000000038767 · Cited by 7
Dias, M., Pinto, L. F., Pinto, M. V., Rosa, R. G. S., Accioli, P., Amorim, G., Guedes, M., Gomes, C. P., Pedrosa, R. C., & Waddington‐Cruz, M. (2024) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0044-1781463 · Cited by 6
Self-citationKršek, A., Batičić, L., & Tokmadžić, V. S. (2024) · Cardiogenetics · doi:10.3390/cardiogenetics14030012 · Cited by 5
Katsuzaki, Y., Tsukimura, R., Chandela, A., Chano, T., & Ueno, Y. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200125 · Cited by 5
It's Time for Effective and Affordable Therapies for Cardiac Amyloidosis: Lessons From Patisiran
Williams, T. M., Harvey, R. E., Fischer, M. A., & Neelankavil, J. P. (2024) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2024.02.035 · Cited by 5
Novel Treatments for Hereditary ATTRv Amyloidosis
González‐Duarte, A. (2023) · JAMA · doi:10.1001/jama.2023.15087 · Cited by 5
Expanding the toolbox: Emerging antisense oligonucleotide mechanisms for modulating gene expression
Trew, I., Wilton, S. D., Cale, J. M., & Aung-Htut, M. T. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102953 · Cited by 2
Onishi, S., Chandela, A., & Ueno, Y. (2024) · ChemistrySelect · doi:10.1002/slct.202305090 · Cited by 2
Amyloidosis is a disease with many faces
Spanggaard, M. B., Hansen, C. T., Maiborg, M., Rojek, A., Vestergaard, S., Beck, H. C., Møller, H. E. H., & Abildgaard, N. (2023) · University of Southern Denmark Research Portal (University of Southern Denmark) · Cited by 2
A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment
Severi, D., Palumbo, G., Spina, E., Iovino, A., Nolano, M., Manganelli, F., & Tozza, S. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06568-w · Cited by 2
POLINEUROPATIA AMILOIDÓTICA FAMILIAR: UMA REVISÃO DE LITERATURA
Monteiro, B. R., & da Fonseca-Neto, O. C. L. (2021) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v24i4.430 · Cited by 1
Neurological Manifestations in ATTRv Amyloidosis
Nascimento, O. J. M., Marques, W., Tomaselli, P. J., & Moreira, C. L. (2023) · Springer eBooks · doi:10.1007/978-3-031-17759-0_2 · Cited by 1
MULTIMODALITY IMAGING IN CARDIAC AMYLOIDOSIS: FROM HISTOPATHOLOGICAL BASIS TO RISK STRATIFICATION
Sinigiani, G. (n.d.) · Padua Research Archive (University of Padova) · Cited by 1
Hope on the horizon: FDA approves eplontersen for hereditary transthyretin-mediated amyloidosis
Anwar, I. B., Ahmed, I. F., Mahmood, F., Haseeb, A., & Ahmed, K. A. H. M. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002839 · Cited by 1
Development and Clinical Applications of Antisense Oligonucleotide Gapmers
Chan, L., Shaikh, F. A., Shah, P., Moriyama, H., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_2
Kachhadia, M. P., Gautam, A., Meadows, S., Kotadiya, S. R., Aryal, R., Ilyas, H., Shaikh, J. D., Gill, G., Shah, S., Patel, J., et al. (2026) · Journal of Clinical Medicine Research · doi:10.14740/jocmr6603
Tafamidís, inotersèn i patisiran per al tractament de l'amiloïdosi transtiretina hereditària
Farmacoterapèutica, P. D. (2020) · RECERCAT (Consorci de Serveis Universitaris de Catalunya)
Müller-Marienburg, N. (2024) · MACAU: Open Access Repository of Kiel University (University Library Kiel)
Metadata
- Authors
- Gertz, M. A., Scheinberg, M., Waddington-Cruz, M., Heitner, S. B., Karam, C., Drachman, B., Khella, S., Whelan, C., & Obici, L.
- Affiliations
- Mayo Clinic (US)
- Hospital Israelita Albert Einstein (BR)
- Neuromuscular Diseases Unit, Federal University of Rio de Janeiro, University Hospital, Rio de Janeiro, Brazil
- Oregon Health & Science University (US)
- University of Pennsylvania (US)
- University College London (GB)
- Policlinico San Matteo Fondazione (IT)
- Corresponding author
- Gertz, Morie A.
- ORCID
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2019-07-03
- Volume
- 12
- Issue
- 8
- Pages
- 701-711
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2955523092
- Cited by
- 38
- References
- 50
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 8 · 2023: 9 · 2022: 6 · 2021: 4 · 2020: 7 · 2019: 1
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Funders
- ApotheCom (01)
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Keywords
- inotersen, hereditary transthyretin amyloidosis, polyneuropathy, antisense oligonucleotides, familial amyloid cardiomyopathy, glomerulonephritis, thrombocytopenia, drug safety and tolerability
- MeSH terms
- Adult, Animals, Humans, Mutation, Oligonucleotides, Polyneuropathies, Prealbumin, Quality of Life, Oligodeoxyribonucleotides, Antisense, Amyloid Neuropathies, Familial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.